You may find more results for this query on our sister sites: GenomeWeb and 360Dx.
Molika Ashford covers personalized medicine and molecular diagnostics for GenomeWeb.
The field is collecting evidence supporting genomics-guided care but experts are still awaiting prospective data and grappling with other challenges.
Presentations at the American Society of Clinical Oncology's virtual annual meeting included new findings relevant to both blood- and spinal fluid-based approaches.
Investigators are building upon an initial case study that allowed them to assess how well ctDNA captured a cancer's full genomic heterogeneity compared to tissue biopsies.
Investigators from the Friends of Cancer Research's tumor mutational burden harmonization project shared new data this week at AACR's virtual meeting.
At the AACR annual meeting, researchers shared detection rate data for multi-cancer screening tests from Grail and Thrive Earlier Detection.
A study of both tissue and blood samples from patients in a small trial found that liquid biopsy may detect putative resistance mutations missed in tissue.
Investigators reported on how ctDNA, measured using Natera's patient-specific Signatera assays, corresponded to a patient's disease progression and other biomarkers.
A new analysis has provided evidence that adjuvant lung cancer immunotherapy benefits those with lingering ctDNA, but not necessary those without.
Researchers are making improvements to viral-DNA detection methods and are exploring applications not just for screening but also disease monitoring.
The company is beginning a multi-site Phase II trial designed to establish that its approach can identify patients who will respond to immuno-oncology drugs.